Patents by Inventor Jean-Laurent Paparin
Jean-Laurent Paparin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11767316Abstract: The present invention relates to a new class of non-fused thiophene derivatives and their uses for treating diseases such as infection, cancer, metabolic diseases, cardiovascular diseases, iron storage disorders and inflammatory disorders.Type: GrantFiled: February 8, 2019Date of Patent: September 26, 2023Assignee: ENYO PHARMAInventors: Eric Meldrum, Benoît De Chassey, Peter Machin, Karine Fabienne Malagu, Paul Colin Michael Winship, Jean-Laurent Paparin, Mark Chambers, Jamie David Knight, Roberta Lanaro
-
Publication number: 20230150978Abstract: The present invention relates to a new class of quinazolinone derivatives of formula (I), and their uses for treating a cancer. The present invention further relates to pharmaceutical compositions comprising compounds of formula (I).Type: ApplicationFiled: March 29, 2021Publication date: May 18, 2023Inventors: LAURÈNE MEYNIEL-SCHICKLIN, PETER MACHIN, ERIC MELDRUM, BENOÎT DE CHASSEY, FABRICE GUILLIER, CHRISTINE MASSARDIER, JÉRÔME AMAUDRUT, CHRISTIAN MONTALBETTI, DAVID COUSIN, JEAN-LAURENT PAPARIN
-
Patent number: 11603368Abstract: The present invention relates to a new class of fused thiophene derivatives and their uses for treating diseases such as infection, cancer, metabolic diseases, cardiovascular diseases, iron storage disorders and inflammatory disorders.Type: GrantFiled: February 8, 2019Date of Patent: March 14, 2023Assignee: ENYO PHARMAInventors: Eric Meldrum, Benoît De Chassey, Peter Machin, Roberta Lanaro, Calum Macleod, Karine Fabienne Malagu, Nicolas Proisy, David Robert Vesey, Paul Colin Michael Winship, Mark Chambers, Jean-Laurent Paparin
-
Publication number: 20220363707Abstract: The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.Type: ApplicationFiled: August 5, 2019Publication date: November 17, 2022Applicants: Merck Sharp & Dohme Corp., MSD International GmbHInventors: Michelle Machacek, David Witter, Craig Gibeau, Chunhui Huang, Shuhei Kawamura, David L. Sloman, Phieng Siliphaivanh, Ryan Quiroz, Murray Wan, Sebastian Schneider, Charles S. Yeung, Michael H. Reutershan, Timothy J. Henderson, Jean-Laurent Paparin, Houcine Rahali, Jonathan M. E. Hughes, Sulagna Sanyal, Yingchun Ye, David A. Candito, Patrick S. Fier, Steven M. Silverman
-
Patent number: 11123355Abstract: Compounds of Formula I: and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.Type: GrantFiled: December 19, 2017Date of Patent: September 21, 2021Assignees: Idenix Pharmaceuticals LLC, Merck Sharp & Dohme Corp.Inventors: Manuel de Lera Ruiz, Timothy J. Hartingh, Izzat Raheem, John Schreier, Jean-Laurent Paparin
-
Publication number: 20210040059Abstract: The present invention relates to a new class of non-fused thiophene derivatives and their uses for treating diseases such as infection, cancer, metabolic diseases, cardiovascular diseases, iron storage disorders and inflammatory disorders.Type: ApplicationFiled: February 8, 2019Publication date: February 11, 2021Inventors: ERIC MELDRUM, BENOÎT DE CHASSEY, PETER MACHIN, KARINE FABIENNE MALAGU, PAUL COLIN MICHAEL WINSHIP, JEAN-LAURENT PAPARIN, MARK CHAMBERS, JAMIE DAVID KNIGHT, ROBERTA LANARO
-
Publication number: 20200369682Abstract: The present invention relates to a new class of fused thiophene derivatives and their uses for treating diseases such as infection, cancer, metabolic diseases, cardiovascular diseases, iron storage disorders and inflammatory disorders.Type: ApplicationFiled: February 8, 2019Publication date: November 26, 2020Inventors: ERIC MELDRUM, BENOÎT DE CHASSEY, PETER MACHIN, ROBERTA LANARO, CALUM MACLEOD, KARINE FABIENNE MALAGU, NICOLAS PROISY, DAVID RICHARD VESEY, PAUL COLIN MICHAEL WINSHIP, MARK CHAMBERS, JEAN-LAURENT PAPARIN
-
Patent number: 10815264Abstract: The present application relates to novel nucleoside derivatives of formula (I) as claimed in claim 1, pharmaceutical compositions comprising the compounds, processes of preparation thereof, and methods of use thereof for treating cancer.Type: GrantFiled: May 25, 2016Date of Patent: October 27, 2020Assignee: Southern Research InstituteInventors: Cyril B. Dousson, David Dukhan, Jean-Laurent Paparin, Christophe C. Parsy
-
Patent number: 10745428Abstract: Compounds of Formula I and pharmaceutically acceptable salts and co-crystals thereof are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.Type: GrantFiled: December 5, 2016Date of Patent: August 18, 2020Assignees: IDENIX PHARMACEUTICALS LLC, MERCK SHARP & DOHME CORP.Inventors: Izzat Tiedje Raheem, Timothy J. Hartingh, John Schreier, Jean-Laurent Paparin
-
Patent number: 10736908Abstract: Compounds of Formula (I): (Formula (I)) and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.Type: GrantFiled: October 20, 2017Date of Patent: August 11, 2020Assignees: MERCK SHARP & DOHME CORP., IDENIX PHARMACEUTICALS LLCInventors: Jean-Laurent Paparin, Houcine Rahali, Aurélien Salanson, Daniel Da Costa, David Dukhan, Timothy J. Hartingh, Izzat Raheem, John Schreier
-
Patent number: 10519159Abstract: Compounds of Formula I: and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.Type: GrantFiled: December 20, 2017Date of Patent: December 31, 2019Assignees: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals, LLC.Inventors: Jean-Laurent Paparin, Izzat Raheem, Houcine Rahali, Daniel Da Costa, David Dukhan
-
Publication number: 20190321380Abstract: Compounds of Formula I: and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.Type: ApplicationFiled: December 19, 2017Publication date: October 24, 2019Applicants: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLCInventors: Manuel de Lera Ruiz, Timothy J. Hartingh, Izzat Raheem, John Schreier, Jean-Laurent Paparin
-
Patent number: 10449208Abstract: Compounds of Formula I: and pharmaceutically acceptable salts and co-crystals thereof are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.Type: GrantFiled: August 22, 2017Date of Patent: October 22, 2019Assignees: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLC.Inventors: Daniel Da Costa, Cyril B. Dousson, David Dukhan, Jean-Laurent Paparin, Houcine Rahali, Izzat Raheem
-
Publication number: 20190262365Abstract: Compounds of Formula (I): (Formula (I)) and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.Type: ApplicationFiled: October 20, 2017Publication date: August 29, 2019Applicants: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLC.Inventors: Jean-Laurent Paparin, Houcine Rahali, Aurélien Salanson, Daniel Da Costa, David Dukhan, Timothy J. Hartingh, Izzat Raheem, John Schreier
-
Publication number: 20190183912Abstract: Compounds of Formula I: and pharmaceutically acceptable salts and co-crystals thereof are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.Type: ApplicationFiled: August 22, 2017Publication date: June 20, 2019Applicants: Merck Sharp & Dohme Corp., IDENIX PHARMACEUTICALS LLCInventors: Daniel Da Costa, Cyril B. Dousson, David Dukhan, Jean-Laurent Paparin, Houcine Rahali, Izzat Raheem
-
Patent number: 10202411Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3?-substituted methyl or alkynyl nucleosides of Formula I: (I); or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, PD, RA, RB1, RB2, RC and Z are as defined herein.Type: GrantFiled: April 16, 2015Date of Patent: February 12, 2019Assignee: IDENIX PHARMACEUTICALS LLCInventors: David Dukhan, Cyril B. Dousson, Gilles Gosselin, Jean-Laurent Paparin, Guillaume Brandt, Rachid Rahali, Aurelien Salanson, François-René Alexandre
-
Publication number: 20180362562Abstract: Compounds of Formula I and pharmaceutically acceptable salts and co-crystals thereof are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.Type: ApplicationFiled: December 5, 2016Publication date: December 20, 2018Applicants: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLCInventors: Izzat Tiedje Raheem, Timothy J. Hartingh, John Schreier, Jean-Laurent Paparin
-
Publication number: 20180208621Abstract: The present application relates to novel nucleoside derivatives of formula (I) as claimed in claim 1, pharmaceutical compositions comprising the compounds, processes of preparation thereof, and methods of use thereof for treating cancer.Type: ApplicationFiled: May 25, 2016Publication date: July 26, 2018Inventors: Cyril B. Dousson, David Dukhan, Jean-Laurent Paparin, Chtirstophe C. Parsy
-
Publication number: 20180179208Abstract: Compounds of Formula I: and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS.Type: ApplicationFiled: December 20, 2017Publication date: June 28, 2018Applicants: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLCInventors: Jean-Laurent Paparin, Izzat Raheem, Houcine Rahali, Daniel Da Costa, David Dukhan
-
Publication number: 20170198005Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?-dichloro or 2?-fluoro-2?-chloro nucleoside analogue compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula (I): or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof; wherein each of RA and RB is independently Cl or F, wherein at least one of RA and RB is Cl; and Base, PD and Z are as described herein.Type: ApplicationFiled: November 26, 2014Publication date: July 13, 2017Applicant: IDENIX PHARMACEUTICALS LLCInventors: Jean-Laurent Paparin, Eric Badaroux, Claire Pierra, Cyril B. Dousson